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Abstract
Background: The activities of mitochondrial complex III (ubiquinol-cytochrome c reductase, EC 1.10.2.2) and
complex IV (cytochrome c oxidase EC 1.9.3.1) are reduced by 30-70% in Huntington’s disease and Alzheimer’s
disease, respectively, and are associated with excitotoxic cell death in these disorders. In this study, we investigated
the control that complexes III and complex IV exert on glutamate release from the isolated nerve terminal.
Results: Inhibition of complex III activity by 60-90% was necessary for a major increase in the rate of Ca
2
+-independent glutamate release to occur from isolated nerve terminals (synaptosomes) depolarized with 4-
aminopyridine or KCl. Similarly, an 85-90% inhibition of complex IV activity was required before a major increase in
the rate of Ca
2+-independent glutamate release from depolarized synaptosomes was observed. Inhibition of
complex III and IV activities by ~ 60% and above was required before rates of glutamate efflux from polarized
synaptosomes were increased.
Conclusions: These results suggest that nerve terminal mitochondria possess high reserves of complex III and IV
activity and that high inhibition thresholds must be reached before excess glutamate is released from the nerve
terminal. The implications of the results in the context of the relationship between electron transport chain
enzyme deficiencies and excitotoxicity in neurodegenerative disorders are discussed.
Background
Glutamate excitotoxicity is thought to occur in chronic
neurodegenerative disorders such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease and amyo-
trophic lateral sclerosis [1,2], and dysfunction of mito-
chondrial electrion transport chain complexes have been
implicated in the pathogenesis of these diseases [3-5].
Reductions in complex II/III activity are specific to the
brain areas affected by the pathogenesis of Huntington’s
disease [6-8]; decreased complex II/III activity in the
caudate (by 29%) and putamen (by 67%) was found in
post-mortem brain tissue, and complex IV activity was
reduced in both regions by 30% and 62% respectively
[6,9]. Complex III deficiencies which occur as a result of
rare mutations can result in the pathogenesis of enca-
phalpathic syndromes of various severity [10,11].
Widespread neurodegeneration throughout the brain
has been shown to occur in Alzheimer’sd i s e a s e ,a n d
postmortem studies on the Alzheimer brain found that
complex IV activity was reduced by 27% in the cerebral
cortex, by 37% in the temporal cortex, and by 52% in
the hippocampus [12,13]. Reductions in the activities of
other mitochondrial enzymes, including complex III,
have also been found [14,15]. A decrease in complex IV
activity in the brain associated with aging is also thought
to occur [16-18] and insufficient control over glutamate
release due to mitochondrial complex III and IV defi-
ciency are thought to contribute to neuronal cell death
[8,19]. During conditions of severe energy stress, release
of glutamate occurs primarily via reversal of plasma
membrane glutamate transporters [20]. The depletion of
intracellular ATP results in plama membrane depolari-
zation and Ca
2+-independent release of glutamate from
the cytoplasmic pool. The resulting increase in extracel-
lular glutamate concentration causes post-synaptic glu-
tamate receptor overactivation, resulting in Ca
2+
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commonly associated with the pathogenesis of acute
neurodegenerative disorders such as stroke and brain
trauma, there is evidence suggesting that a similar
‘slower’ form of excitotoxicity contributes to chronic
neurodegeneration [21].
Previous studies have examined the effects of total
inhibition of complex IV activity using NaCN on gluta-
mate release [22-25], which indicated that an increase in
Ca
2+-independent glutamate efflux from polarized
synaptosomes occurs due to severe depletion of nerve
terminal ATP content [24]. Under these conditions,
insufficient ATP supply to the plasma membrane Na
+/K
+ ATPase results in depolarization, and Ca
2+-indepen-
dent release of glutamate via reversal of glutamate trans-
porters [26]. Complex I exerts a high level of flux
control over oxidative phosphorylation in in situ synap-
tosomal mitochondria [27] and a 40% inhibition of com-
plex I activity results in an increase in Ca
2+-independent
glutamate release from depolarized synaptosomes [28].
However, the effects of partial inhibition of complexes
III and IV on glutamate release from nerve terminal
preparations remain unknown.
Complexes III and IV have been shown to have high
thresholds of inhibition of activity before major changes
in oxygen consumption and ATP production occur in
isolated brain mitochondria [29,30]. Comparison of such
data obtained from experiments carried out on isolated
nerve terminal mitochondria [31] with nonsynaptic
mitochondria [32,33] indicate the threshold levels are
higher in synaptosomal mitochondria for both complex
III and complex IV respectively. This suggests that com-
plexes III and IV have relatively low levels of control
over oxidative phosphorylation in isolated synaptosomal
mitochondria. Recently we demonstrated that both com-
plex III and complex IV have lower control over oxygen
consumption in in situ synaptosomal mitochondria than
complex I [27]. To examine the control of complexes III
and IV over glutamate release from nerve terminals,
experiments using ranges of concentrations of the com-
plex III inhibitors myxothiazol and antimycin A, which
inhibit complex III activity upstream and downstream of
the Q-cycle respectively [34], and a range of concentra-
tions of the complex IV inhibitor KCN on glutamate
release rates were carried out. Such data may be rele-
vent to elucidating the role of excitotoxicity in the
pathogenesis of neurodegenerative disorders.
Results
Complex III-related loss of nerve terminal control over
glutamate release
We have previously demonstrated that inhibition of com-
plex III activity in synaptic mitochondria by up to 80%
does not result in any major reductions in oxidative
phosphorylation [33]. This suggests that a high threshold
of inhibition of complex III activity must be exceeded
before effects on mitochondrial oxygen consumption and
ATP production occur. However, this threshold was found
to be lower in in situ synaptosomal mitochondria [27]. A
low threshold of inhibition was consistantly shown to exist
for complex I [27,35], which correlated to a loss of synap-
tosomal control over Ca
2+-independent glutamate release
at low level inhibition of complex I activity [28,36]. In the
present study, we examined the downstream effects of
inhibition of complex III activity on synaptosomal control
over Ca
2+-independent glutamate release. We found that
inhibition of complex III activity by > 60% increased gluta-
mate release to almost 250 pmol/min/mg protein from
synaptosomes depolarized with 4-aminopyridine (Figure
1A). However, low-level inhibition did not effect glutamate
release, evidence that a complex III inhibition threshold
must be exceeded before synaptosomal control over cyto-
plasmic glutamate retention is lost. Furthermore, inhibi-
tion by up to 80% did not affect KCl-induced Ca
2
+-independent glutamate release (Figure 1B), suggesting
the occurrence of a similar threshold of inhibition to that
found in isolated synaptic mitochondria. Inhibition of
complex III activity by > 60% also increased glutamate
efflux from synaptosomes in the absence of either depolar-
izing agent, although the peak rate of release was slower
(~100 pmol/min/mg protein, Figure 2).
Inhibition of complex III activity at the Qi site with
antimycin A also increased glutamate release in depolar-
ized synaptosomes (Figures 3A &3B). However, inhibi-
tion by > 90% was required to elicit the increase, and a
similar level of inhibition was required to increase gluta-
mate efflux from polarized synaptosomes (Figure 4).
This suggests that the inhibition thresholds that are
required to be exceeded before glutamate release is
effected may be heterogeneous within a single respira-
tory complex, depending on the site of inhibition.
Complex IV-related loss of nerve terminal control over
glutamate release
It has been established that high thresholds of inhibition
of complex IV activity must to be exceeded before oxy-
gen consumption is effected in nerve terminal mito-
chondria, evidenced in both isolated [31,33] and in situ
[27] models. Total inhibition of complex IV activity
using NaCN has been used as a model of anoxia, and
has been shown to increase glutamate efflux from rest-
ing synaptosomes [22,23]. Here, we used a range of con-
centrations of KCN to establish the extent that complex
IV activity controls glutamate release from depolarized
and polarized synaptosomes. We found that 90% inhibi-
tion of complex IV activity was required to increase the
rate of Ca
2+-independent glutamate release from synap-
tosomes depolarized with 4-aminopyridine (Figure 5A).
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Page 2 of 9Overcoming a similarly high inhibition threshold was
required to elicit an increase in glutamate release from
synaptosomes depolarized with KCl (Figure 5B). In rest-
ing synaptosomes, in accordance with previous studies,
we found that 1 mM KCN increased glutamate efflux,
correlating to ~ 90% inhibition of complex IV activity
(Figure 6). However, the rate was not affected by any
lower concentration of KCN.
ATP depletion caused by inhibition of complex III and IV
In the absence of complex III or IV inhibitors, polarized
and depolarized synaptosomes maintained their ATP levels
close to control levels (Figure 7). Incubation with 50 nM
myxothiazol reduced the ATP levels to approximately 80%
of the control levels in all 3 groups. Myxothiazol concen-
trations of 1 and 10 μM lowered the ATP levels to 52 and
40% in polarized synaptosomes, respectively. However,
depolarization with 4-aminopyridine potentiated the myx-
othiazol-induced ATP depletion to 40 and 18% with 1 and
10 μM myxothiazol, respectively. Addition of 100 nM anti-
mycin A reduced ATP levels to 38% in polarized synapto-
somes and to 28% in depolarized synaptosomes. Inhibition
of complex IV activity by 0.1 and 1 mM KCN significantly
reduced ATP levels to approximately 70% and 10%, respec-
tively, in both polarized and depolarized synaptosomes.
Discussion
The results in this study indicate that high level inhibi-
tion of complex III and IV activities of in situ
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Figure 1 High-level inhibition of complex III activity with
myxothiazol is required to increase the rate of glutamate
release from depolarized synaptosomes. Synaptosomes (0.5 mg/
ml) were preincubated at 37°C for 5 min before being depolarized
with A 1 mM 4-aminopyridine or B 40 mM KCl. Rates of glutamate
release at each concentration of myxothiazol were plotted against
percent inhibition of complex III activity brought about by that
concentration of myxothiazol. Freehand curves were drawn through
the results. Points shown represent the mean ± SEM for
experiments carried out in triplicate on at least 3 separate
synaptosomal preparations.
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Figure 2 High-level inhibition of complex III activity with
myxothiazol is required to increase the rate of glutamate
efflux from polarized synaptosomes. Synaptosomes (0.5 mg/ml)
were preincubated at 37°C for 5 min. Rates of glutamate release at
each concentration of myxothiazol were plotted against percent
inhibition of complex III activity brought about by that
concentration of myxothiazol. Freehand curves were drawn through
the results. Points shown represent the mean ± SEM for
experiments carried out in triplicate on at least 3 separate
synaptosomal preparations.
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Page 3 of 9synaptosomal mitochondria are required to increase Ca
2
+-independent glutamate release rates from depolarized
synaptosomes, as well as the Ca
2+-independent gluta-
mate efflux rate from resting synaptsomes. Inhibition of
complex III activity by more than 50% with myxothiazol
was required to increase glutamate release from depolar-
ized and polarized synaptosomes. Complex III activity
could be inhibited by up to 90% with antimycin A
before KCl- or 4-aminopyridine-induced release or glu-
tamate efflux was affected. A similarly high threshold of
inhibition was found when complex IV was inhibited
with KCN. Previously we have shown that inhibition of
complex I activity by approximately 40% increases the
rate of Ca
2+-independent glutamate release from depo-
larized synaptosomes [28]. This suggests that complex I
has greater control over the release cytosolic pool of
glutamate in the depolarized nerve terminal model than
complex III or complex IV. However, we also showed
that in polarized synaptosomes, glutamate efflux was not
affected by any level of inhibition of complex I activity
[28], whereas in the present study it was demonstrated
that inhibition of complex III or complex IV caused an
increase in glutamate efflux at the highest levels of
inhibition.
Using a range of myxothiazol concentrations, inhibition
of complex III activity by up to 80% did not result in
major changes in oxidative phosphorylation, while inhibi-
tion by 90% completely abolished the oxygen consumption
and ATP production in mitochondria isolated from
A
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Figure 3 High-level inhibition of complex III activity with
antimycin A is required to increase the rate of glutamate
release from depolarized synaptosomes. Synaptosomes (0.5 mg/
ml) were preincubated at 37°C for 5 min before being depolarized
with A 1 mM 4-aminopyridine or B 40 mM KCl. Rates of glutamate
release at each concentration of antimycin A were plotted against
percent inhibition of complex III activity brought about by that
concentration of antimycin A. Freehand curves were drawn through
the results. Points shown represent the mean ± SEM for
experiments carried out in triplicate on at least 3 separate
synaptosomal preparations.
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Figure 4 High level inhibition of complex III activity with
antimycin A is required to increase the rate of glutamate
efflux from polarized synaptosomes. Synaptosomes (0.5 mg/ml)
were preincubated at 37°C for 5 min. Rates of glutamate release at
each concentration of antimycin A were plotted against percent
inhibition of complex III activity brought about by that
concentration of antimycin A. Freehand curves were drawn through
the results. Points shown represent the mean ± SEM for
experiments carried out in triplicate on at least 3 separate
synaptosomal preparations.
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Page 4 of 9synaptosomes [33]. However, the threshold level of inhibi-
tion of complex III activity on oxygen consumption in in
situ synaptosomal mitochondria was found to be lower
than that reported in isolated synaptic mitochondria [27].
In the in situ synaptosomal mitochondrial model, inhibi-
tion of complex III activity by 70% with myxothiazol was
found to almost completely abolish the oxygen consump-
tion rate [27]. At this level of inhibition mitochondrial
ATP synthesis is also minimal (as oxygen consumption is
tightly coupled to ATP synthesis in nerve terminals [37]).
In the present study we found that ATP levels in polarized
synaptosomes were decreased by 60% by 10 μM myxothia-
zol. Under resting conditions glycolysis is thought to
account for the remaining ATP synthesis [37]. Glutamate
efflux from ‘polarized’ synaptosomes was found to occur
at a maximum of 70% inhibition of complex III activity
and Ca2+-independent glutamate release from synapto-
somes depolarized with 4-aminopyridine over the same
range of inhibition of complex III activity with myxothia-
zol (between 50 - 70%) was 2.5-fold higher than from
polarized synaptosomes. This increase in the rate of gluta-
mate release correlated with an extra 20% reduction in
ATP levels induced by 4-aminopyridine in combination
with myxothiazol-related inhibition of complex III activity.
This suggests that the control of complex III over oxida-
tive phosphorylation in synaptosomes is similar to the
control of complex III over glutamate release rates from
synaptosomes.
Interestingly, glutamate release returned towards con-
trol levels as inhibition of complex III neared 100%.
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Figure 5 High-level inhibition of complex IV activity with KCN
is required to increase the rate of glutamate release from
depolarized synaptosomes. Synaptosomes (0.5 mg/ml) were
preincubated at 37°C for 5 min before being depolarized with A 1
mM 4-aminopyridine or B 40 mM KCl. Rates of glutamate release at
each concentration of KCN were plotted against percent inhibition
of complex IV activity brought about by that concentration of KCN.
Freehand curves were drawn through the results. Points shown
represent the mean ± SEM for experiments carried out in triplicate
on at least 3 separate synaptosomal preparations.
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Figure 6 High-level inhibition of complex IV activity with KCN
is required to increase the rate of glutamate efflux from
polarized synaptosomes. Synaptosomes (0.5 mg/ml) were
preincubated at 37°C for 5 min and rates of glutamate release at
each concentration of KCN were plotted against percent inhibition
of complex IV activity brought about by that concentration of KCN.
Freehand curves were drawn through the results. Points shown
represent the mean ± SEM for experiments carried out in triplicate
on at least 3 separate synaptosomal preparations.
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Page 5 of 9This is similar to the effect observed on Ca
2+-indepen-
dent glutamate release from depolarized synaptosomes
following inhibition of complex I activity [28]. A short-
term plasma membrane potential hyperpolarization
response by neurons to extreme energy stress has been
previously demonstrated [39]. This phenomenon may be
related to the presence of ATP-sensitive K
+ channels on
the plasma membrane [38], which open during periods
of severe ATP depletion (correlating to an approxi-
mately 90% reduction in ATP levels in our experiments),
and are thought to allow short term maintainance of the
K
+ gradient across the plasma membrane when the Na
+/K
+ ATPase activity is compromised [39].
The highest rates of Ca
2+-independent glutamate
release brought about by complex III inhibition with
antimycin A were similar to those with myxothiazol.
However, 80% inhibition of complex III activity with
antimycin A did not increase Ca
2+-independent gluta-
mate release rates from synaptosomes depolarized with
4-aminopyridine, while maximum 4-aminopyridine-
induced glutamate release rates were recorded at less
than 80% inhibition of complex III activity with myx-
othiazol. Similarly, 80% inhibition of complex III activity
with antimycin A did not increase glutamate efflux rates
from ‘polarized’ synaptosomes while maximum gluta-
mate efflux rates were recorded at less than 80% inhibi-
tion of complex III activity with myxothiazol. This
suggests that complex III of in situ nerve terminal mito-
chondria may have a lower energy threshold when
inhibited upstream of the Q-cycle with myxothiazol
than when inhibited downstream with antimycin A,
which results in increased rates of glutamate release at a
lower level of inhibition.
Inhibition of complex IV activity by > 90% with KCN
also increased Ca
2+-independent glutamate release rates
from synaptosomes depolarized with 4-aminopyridine or
KCl, and increased glutamate efflux from ‘polarized’
synaptosomes. A similar increase in glutamate efflux has
previously been reported in rat brain synaptosomes
when 2 mM NaCN was added, and was related to a fall
in ATP/ADP ratio [24]. Inhibition of complex IV activity
by up to 70% with KCN in isolated synaptosomal mito-
chondria has previously been shown to decrease ATP
production by less than 10%, with total inhibition of
ATP production at 90% inhibition of complex IV activ-
ity [33]. The similar threshold effect found in in situ
synaptosomal mitochondria [27] might explain the
effects of complex IV inhibition on Ca
2+-independent
glutamate release from depolarized synaptosomes.
Conclusions
Reduced complex II/III activity may play a role in the
excitotoxic mechanism thought to occur during the
pathogenesis of Huntington’s disease [6-8], and reduced
complex IV activity has been consistantly observed in
post mortem Alzheimer’s disease brain samples [14].
Neurodegeneration has been proposed to progress from
the nerve terminal to the neuronal soma in these
chronic neurdegenerative disorders [40]. Indeed, ETC
enzyme activities in the brain have been shown to be
reduced as part of the aging process [41,42]. However,
the model of the effects of reduced activities of complex
III and complex IV nerve terminal glutamate release in
the present study indicate that these enzymes must be
inhibited by at least 50% (for complex III) or 90% (for
complex IV) before major increases in glutamate release
rates are observed. Such large reductions in activity are
usually related to mutations in either the mitochondrial
or nuclear DNA encoding components of the com-
plexes, and usually result in severe metabolic disorders
which are often fatal [10,11]. However, our model may
support a role for excessive nerve terminal glutamate
release during pathogenesis of encephalopathies caused
by complex III and IV deficiencies, in which seizures are
commonly reported.
A lower level of inhibition of complex I activity is
required to reduce nerve terminal oxygen consumption
[27] and increase Ca
2+-independent glutamate release
rates from depolarized nerve terminals than complex III
or IV [28]. Nonetheless, inhibition of complex I activity
by up to 100% did not affect glutamate efflux from rest-
ing synaptosomes [28], while inhibition of complexes III
and IV increased the efflux rate, although a high level of
inhibition was required. This indicates that both com-
plex III and complex IV exert greater control over gluta-
mate release from resting nerve terminals than complex
I. However, given that the complex I threshold for Ca
2
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Figure 7 Partial inhibition of complexes III and IV depletes ATP
levels in synaptosomes. Synaptosomes (0.5 mg/mL) were divided
into groups and incubated at 37°C with 10 mM glucose and
inhibitors as indicated. ATP from polarized synaptosomes was PCA
extracted after 15 min incubation. In the depolarised groups 4-AP
and KCl were added following 5 min incubation with inhibitors.
Results are expressed as a percentage of the initial [ATP] at zero
time (439.4 ± 42.6 pmol/mg protein) and represent the mean ±
SEM for experiments carried out on three separate synaptosomal
preparations. *p < 0.05.
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somes isolated from aged rats is even lower than that
from young rats [36] coupled with the findings that
complex I activity is decreased in mitochondria isolated
from Parkinson’s disease post mortem samples [43-45],
the evidence is mounting that of the ETC enzymes that
are found to be reduced in the most common chronic
neurodegenerative disorders, complex I is the most
important.
Materials and methods
Materials
Chemicals were supplied by Sigma Chemical Co., Poole,
Dorset, UK or BDH, Dagenham, Essex, UK. Female
Wistar rats (200-250 g) were supplied by the Biore-
sources Unit, Biochemistry Department, Trinity College,
Dublin.
Synaptosomal preparation
Rats were killed by cervical dislocation and synapto-
somes were prepared using a discontinuous ficoll gradi-
ent (7.5% w/v and 10% w/v), acording to the method of
Lai and Clark [46]. Synaptosomes (1 mg) were resus-
pended in TES buffer (250 mM sucrose/5 mM TES, pH
7.4) and following centrifugation at 15000 g for 5 min
were stored as 1 mg pellets on ice for use within 2
hours of preparation. All experiments were carried out
on at least 3 separate synaptosomal preparations to
ensure reproducibility of results.
Glutamate release
Glutamate release was measured on a SpectraMAX
GeminiXS (Molecular Devices, CA) well plate reader
using a continuous flourimetric assay modified from
that described by Nicholls et al. [47]. Synaptosomal pel-
lets were resuspended in 1 ml of incubation medium (3
mM KCl, 140 mM NaCl, 25 mM Tris-HCl, 10 mM glu-
cose, 2 mM MgCl2, pH 7.4). 100 μlo fi n c u b a t i o nm e d -
ium containing 2 mM NADP
+,6 . 3 2UL - g l u t a m i c
dehydrogenase, (and 1.4 mM CaCl2 where appropriate)
was distributed into each of the 96 wells. 2 μl of each
respective mitochondrial electron transport chain
enzyme inhibitor (final concen t r a t i o n sa sf o l l o w s :m y x -
othiazol, 10 nM - 10 μM; antimycin A, 1 nM - 1 μM; or
KCN, 1 μM-1m M ; )w a sa d d e df o l l o w e db y1 0 0μlo f
resuspended synaptosomes (final concentration 0.5 mg/
ml) and each experimental condition was carried out in
triplicate on each plate. Synaptosomes were depolarized
after 5 minutes and rate of increase in NADPH fluores-
cence at l = 460 nm emission (340 nm excitation) was
recorded over a 20 minute time period at a 32 second
interval following depolarization. Linear rates were fitted
to the traces by the SoftMax Pro program, which
accompanies the instrument, and these rates were
calibrated using a standard curve. Enzyme lag [47] was
accounted for when converting rates to nmol/min/mg
protein.
Complex III activity assay
Complex III activity was measured using a SpectraMAX
340PC well-plate spectrophotometer. The titration of
complex III activity with myxothiazol (10 nM - 10 μM)
or antimycin A (1 nM - 1 μM) was carried out identi-
cally to the glutamate release experiments in which
synaptosomes (0.5 mg/ml) were incubated with inhibitor
af i n a lv o l u m eo f2 0 2μl. Samples were frozen at -80°C
and subsequently underwent 3 rapid freeze-thaw cycles.
Complex III activity was determined by following the
reduction of cytochrome c at absorbance l = 550 nm.
Decylubiquinol was used as the electron donor and was
prepared by reducing decylubiquinone with sodium bor-
ohydride and extraction under nitrogen in cylohexane/
diehyl ether. Wells were prepared by addition of med-
ium containing 100 mM potassium phosphate, 0.3 mM
potassium-EDTA, (pH 7.4), 1 mM KCN and 100 μM
cytochrome c with a final volume of 200 μl. The reac-
tion was initiated by the addition of sample (10 μg) and
results were expressed as a percentage of first order
decay rate constants (k).
Complex IV activity assay
Complex IV activity was measured using an Agilent
ChemStation 8453 spectrophotometer. The titration of
complex IV activity with KCN was also carried out iden-
tically to the glutamate release experiments, where
synaptosomes (0.5 mg/ml) were incubated in a final
volume of 202 μl with inhibitor. After freezing at -80°C
and undergoing 3 rapid freeze-thaw cycles, the activity
of complex IV was determined using the method of
Wharton and Tzagoloff [48]: The oxidation of cyto-
chrome c at absorbance l = 550 nm was followed.
Reduced cytochrome c was prepared by the addition a
few crystals of ascorbic acid to oxidised cytochrome c
( 2 5m g / 2 . 5m li nH 2O). Excess ascorbic acid was
removed by passing the cytochrome c sample through a
PD10 gel filtration column, which had been pre-rinsed
with 50 ml 1:10 (v/v) dilution of potassium phosphate
buffer (100 mM), pH 7.0. The assay cuvettes contained
50 μM reduced cytochrome c and 100 μlb u f f e rw i t ha
f i n a lv o l u m eo f1m lm a d eu pw i t hH 2O. The reaction
was initiated by the addition of 50 μg synaptosomal
samples. The results were expressed as a percentage of
first order decay rate constants (k).
ATP determinations
ATP levels were determined using a luciferase coupled
assay [28]. Synaptosomes (1 mg/mL) were pre-incubated
at 37°C for 5 min in incubation medium containing 10
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Page 7 of 9mM glucose. After 5 min 100 μL synaptosomes were
added to 100 μL of incubation medium with 2 μL myx-
othiazol, antimycin or KCN added, where appropriate.
One group was prepared for ATP determination imme-
d i a t e l ya tt h i sp o i n t ,b ya d d i n g1 0μL 6.5 M perchloric
acid and, after centrifugation, neutralizing 150 μLo f
supernatant with 375 μL1MK 2HPO4.A n o t h e rg r o u p
was depolarized after 5 min (with 1 mM 4-aminopyri-
dine). [ATP] is expressed as a percentage of the control
group that contained no complex III or IV inhibitors.
These groups were perchloric acid extracted in the same
way 10 min after depolarization and all samples were
then stored at -80°C. 10 μL of extract was added to 100
μL reconstituted luciferin/luciferase ENLITEN
® reagent
and read immediately at 560 nm. All samples were
assayed within 1 week of preparation.
Statistical analysis
Results presented are mean ± SEM values. Statistical
analysis of the results were determined by doing a one-
w a yA N O V Af o l l o w e db yaN e w m a n - K e u l sp o s t - h o c
test. Values of p < 0.05 were taken to be significant.
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